Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Experimental · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | TRO19622 |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Experimental | DRUG | Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks |
| Placebo comparator | DRUG | 4 Capsules of PBO per day before noon meal |
Inclusion Criteria: * Be a male \>18 years or a post-menopausal female (\>60 years of age and at least 1 year of amenorrhea). * Have painful diabetic neuropathy of \>6 months duration and are either pain treatment naive or have important side effects or inadequate relief from their current pain med...
Experimental is an investigational small molecule being studied for the treatment of painful peripheral diabetic neuropathy. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its potential to address this neurological condition associated with diabetes.
Experimental is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded over-the-counter under the ticker symbol RHHBY. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug for diabetic neuropathy.
Experimental is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug remains investigational and has not received approval from regulatory agencies. Further clinical studies may be needed to establish its safety and effectiveness.
Experimental has been studied in one completed Phase 2 clinical trial, registered as NCT00496457. This study evaluated the efficacy of a 500 mg daily dose of the drug compared to placebo in patients with painful peripheral diabetic neuropathy. The trial enrolled 159 participants across Croatia, Germany, Latvia, Poland, and Serbia.
Yes, Experimental is also known as TRO19622. The completed Phase 2 clinical trial NCT00496457 used the name TRO19622 to refer to the drug. This alternative name may appear in scientific literature and clinical trial registries, while Experimental is used as the development name.